Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donald Wender

Hematology & Oncology Sioux City, IA Medical Doctor

NPI 1861463275 CMS profile 311760

230 Nebraska St, Sioux City, IA 51101

Open in the dashboard

General payments

$22,111

1,016 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,265,986 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Donald Wender of Sioux City, IA is reported in the CMS Open Payments database as having received $22,111 across 1,016 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,265,986 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 82nd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,300 115
2024 General $2,979 160
2023 General $3,225 177
2022 General $5,006 174
2021 General $2,824 167
2020 General $1,212 79
2019 General $4,566 144

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Wender
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Donald Wender were reported at $2,300. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Donald Wender Hematology & Oncology median Middle half National median
2019 $4,566 $529 $121–$2,516 $163
2020 $1,212 $339 $82–$2,213 $114
2021 $2,824 $263 $49–$1,965 $132
2022 $5,006 $416 $103–$2,395 $149
2023 $3,225 $542 $125–$2,646 $160
2024 $2,979 $692 $141–$3,008 $164
2025 $2,300 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $3,239 51 payments
  2. Celgene Corporation $1,773 30 payments
  3. Ipsen Biopharmaceuticals, Inc $1,264 10 payments
  4. E.R. Squibb & Sons, L.L.C. $975 69 payments
  5. Janssen Biotech, Inc. $943 43 payments
  6. Seattle Genetics, Inc. $929 64 payments
  7. Merck Sharp & Dohme Corporation $885 60 payments
  8. Novartis Pharmaceuticals Corporation $784 47 payments
  9. Genentech USA, Inc. $718 43 payments
  10. Genzyme Corporation $675 49 payments
  11. Other $9,926 550 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,127 964 payments
  2. Consulting Fee $4,500 3 payments
  3. Education $2,370 46 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $115 3 payments
Products named General payments · program years 2019–2025
  1. CALQUENCE $2,482 16 payments
  2. Revlimid $1,350 1 payment
  3. ONIVYDE $1,108 7 payments
  4. KEYTRUDA $828 56 payments
  5. OPDIVO $710 53 payments
  6. TECENTRIQ $530 27 payments
  7. ENHERTU $437 32 payments
  8. DARZALEX $411 20 payments
  9. Lenvima $407 26 payments
  10. ADCETRIS $321 31 payments
  11. Other $16,225 986 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,917

Median for Hematology-Oncology: 604

Drug cost

$5,428,291

Median for Hematology-Oncology: $1,306,514

Branded share of claims

25.5%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Revlimid Lenalidomide Brand 66 $1,167,184
Calquence Acalabrutinib Maleate Brand 59 $732,040
Imbruvica Ibrutinib Brand 40 $611,978
Lenalidomide Generic 43 $554,528
Kisqali Ribociclib Succinate Brand 24 $380,335
Cabometyx Cabozantinib S-Malate Brand 14 $321,663
Ibrance Palbociclib Brand 20 $319,398
Xtandi Enzalutamide Brand 29 $281,549
Tagrisso Osimertinib Mesylate Brand 17 $239,731
Lynparza Olaparib Brand 21 $223,354

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 212 billing codes

Paid by Medicare

$6,575,474

Of which drugs: $5,186,016

Medicare patients

1,459

Average age 75

Services billed

264,002

769 women, 690 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Cancer 58%
Arthritis 38%
Chronic kidney disease 31%
Diabetes 29%
COPD 29%
Ischemic heart disease 26%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 42 33,000 $1,474,658
Injection, nivolumab, 1 mg J9299 Office 22 32,100 $760,427
Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 Office 14 11,160 $433,298
Injection, denosumab, 1 mg J0897 Office 38 6,960 $141,166
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 Office 11 3,470 $122,875
Injection, rituximab-abbs, biosimilar, (truxima), 10 mg Q5115 Office 14 1,880 $48,706
Injection, fulvestrant, 25 mg J9395 Office 13 660 $4,152
Injection, leucovorin calcium, per 50 mg J0640 Office 23 1,151 $3,581
Injection, alteplase recombinant, 1 mg J2997 Office 17 40 $2,520
Injection, fosaprepitant, 1 mg J1453 Office 56 19,350 $2,134

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 82 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
$148 — —
CARVYKTI
$130 — —
OPDIVO
$115 — 32,100
BESREMI
$92 11 —
KEYTRUDA
$84 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 82 with Patron

Records

1,016 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record